bioihbjkbjnl/mcl2 huggingface dataset:
Cross-sectional Study of Ultrasonic Diagnosis of Iliac Joint Capsule Muscle
Condition: Femoroacetabular Impingement; Hip Developmental Dysplasia
MeSH terms: Femoracetabular Impingement
Study type: Observational

Summary: 
      In order to investigate the relationship between the iliac joint capsular muscle and the
      development of the hip joint, this study used ultrasound Doppler to measure the anatomical
      circumference of the iliac joint capsular muscle to explore the relationship
    

Detailed description: 
      In order to investigate the relationship between the iliac joint capsular muscle and the
      development of the hip joint, this study used ultrasound Doppler to measure the anatomical
      circumference of the iliac joint capsular muscle to explore the relationship.Ultrasound was
      used to compare the size of the iliac joint cystic muscle in the three groups: patients with
      developmental dysplasia of the hip (DDH), patients with Pincer type femoral hip impingement,
      and normal control group. The shear wave velocity and shear modulus of the iliac joint
      capsular muscle of three groups were compared to compare the degree of fat infiltration in
      muscle.
    

Intervention name(s): ultrasound Doppler
Intervention type(s): Device
Intervention description(s): A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
Observational model: Case-Control
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Patients who were admitted to the sports medicine outpatient department of Peking
        University Third Hospital for hip surgery and volunteers recruited as control
        group，including 40 patients with developmental dysplasia of the hip 40 femoroacetabular
        impingement patients and 40 healthy volunteers as the control group.
Picosecond Laser for Ttreatment of Benign Pigmented Lesions
Condition: Benign Pigmented Lesions
Study type: Interventional

Summary: 
      The purpose of this study is to determine whether Pico laser is effective and safe in the
      treatment of benign pigmented lesions.
    

Detailed description: 
      The Investigational device is a dual wavelength laser system developed for treatment of
      pigmented lesions and for tattoo removal. The base unit is a GentleMax system modified to
      emit light at wavelengths of 532 and 1064 nm and deliver pulse energy up to 400mJ, and pulse
      duration of 700 ps.
    

Intervention name(s): GentleMax system
Intervention type(s): Device
Intervention description(s): Picosecond Laser System for the Treatment of Pigmented Lesions
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Pigmented Lesions, Skin Pigment, Picosecond Laser, Syneron
Evaluation of Relapse Presence in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis Relapse
MeSH terms: Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sclerosis; Recurrence
Study type: Observational [Patient Registry]

Summary: 
      Purpose: This study aims to investigate the demonstrability of increased inflammation and
      neurodegeneration in multiple sclerosis (MS) patients in relapse period compared to MS
      patients in remission by cross-sectional analysis of in-vivo corneal confocal microscopy
      (IVCM), and to evaluate the alternations with a second IVCM administered at least 6 months
      after the relapse period.

      Methods: This prospective, non-randomized-controlled, cross-sectional study included 58 MS
      patients which were grouped regarding the presence of relapse (MS-Relapse group [n=27] and
      MS-Control group [n=31]), and age-sex matched 30 healthy controls (HC). The corneal nerve
      fiber density (CNFD), the corneal nerve branch density (CNBD), the corneal nerve fiber length
      (CNFL), and dendritic cell (DC) density were evaluated in all MS patients and HCs by IVCM. If
      the patients in the MS-relapse group did not have an attack within 6 months, the same
      parameters were evaluated with the second IVCM. The patients with a history of optic neuritis
      or trigeminal symptoms were excluded.
    


Intervention name(s): in-vivo Corneal Confocal Microscopy
Intervention type(s): Diagnostic Test
Intervention description(s): All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
Observational model: Case-Control
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        Fifty-eight patients with RRMS and 30 HCs were included in the study. The RRMS patients
        were divided into two subgroups: 1) Thirty-one patients (MS-Control) who were followed up
        with the diagnosis of RRMS, 2) Twenty-seven patients (MS-Relapse) for whom the
        administration of intravenous corticosteroids was decided due to the diagnosis of new
        relapse.
      
Keywords: multiple sclerosis, in-vivo corneal confocal microscopy, relapse, inflammation, neurodegeneration, neuroregeneration
Vascular CT Assessment of Structural Autograft and Allograft Healing
Condition: Bone Tumors
MeSH terms: Bone Neoplasms
Study type: Observational

Summary: 
      The purpose of this study is to determine the ability of a cone beam CT to measure bone
      healing.
    

Detailed description: 
      The purpose of this study is to investigate quantitative vascular cone beam CT(CBCT) in a
      clinical pilot of patients that have received a structural allograft for bone cancer or a
      vascularized structural autograft for bone cancer or traumatic injury. Development of a
      minimally invasive, longitudinal outcome measure to quantify intramedullary vascular volume
      and cortical bone volume of structural allografts in patients is required to translate
      "revitalizing" structural allograft in clinical trials. Our novel vascular CBCT will be able
      to demonstrate the significant differences between vascularized fibular autografts vs.
      structural allografts in patients that will undergo structural grafting. These data will be
      used to devise a power calculation for a definitive clinical trial to evaluate the efficacy
      of the revitalizing allograft.
    

Intervention name(s): Cone Beam CT Scan
Intervention type(s): Device
Intervention description(s): The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patients are recruited from the general practice of 3 of our investigators. Patients will
        have received an structural allograft or vascularized autograft for the treatment of bone
        cancer.
      
Keywords: Cone Beam CT; CBCT; Bone Tumors; Autographs; Allographs
Zinc Supplementation and Nutrition Education Among Children in the Rural Community
Condition: Effects of; Serum
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      Malnutrition among children, especially stunting is a public health problem in Cameroon. This
      study assesses the impact of zinc supplementation of children and nutrition education of
      mothers on the nutritional status of the children in the rural community. Dietary surveys,
      nutritional status, zinc supplementation of children and nutrition education of mothers were
      carried out. After nutrition education and zinc supplementation, the study showed positive
      impact of both intervention on the nutritional status of children.
    

Detailed description: 
      A questionnaire was developed, tested and adjusted prior the field survey. During the study,
      the knowledge of mothers on child nutrition, the eating habits of children, the estimated
      consumption of energy, nutrients of children and food availability on the market during
      harvesting and sowing seasons were evaluated. Moreover, data on zinc supplementation and
      nutrition education sessions conducted with mothers of these children were collected. The
      impact of zinc supplementation and maternal education was evaluated by measuring height/age,
      weight/age and weight/height indices, and levels of serum albumin, calcium, zinc, iron,
      magnesium and phosphorus before and after interventions.
    

Intervention name(s): Zinc Supplementation; Nutrition education of mothers
Intervention type(s): Drug; Behavioral
Intervention description(s): The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.; Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
Other intervention name(s): Supplementation; Maternal education
Allocation: Randomized
Intervention model: Single Group Assignment
Intervention model description: Evaluation of the anthropometric and biochemistry parameters of children before and after an intervention.
Masking: None (Open Label)
Primary purpose: Treatment
Study of Acetaminophen (ACE) in Post-operative Dental Pain
Condition: Dental Pain
MeSH terms: Toothache
Study type: Interventional
Phase: Phase 2

Summary: 
      This is a dental pain study evaluating the efficacy and safety of a single dose of test
      acetaminophen (ACE) (1000 mg) compared to commercial acetaminophen (1000 mg), ibuprofen (IBU)
      (400 mg), and placebo over a 6 hour period. Subjects will undergo dental extraction of three
      or four third molars.
    


Intervention name(s): Acetaminophen (ACE) (1000 mg); Commercial ACE (1000 mg); Commercial Ibuprofen (IBU) (400 mg); Placebo; Placebo; Placebo
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): 2 Test ACE 500 mg tablets taken orally one time; 2 ACE 500 mg caplets taken orally one time; 2 IBU 200 mg soft-gels taken orally one time; 2 placebo caplets for acetaminophen taken orally one time; 2 placebo soft-gels for ibuprofen taken orally one time; 2 placebo tablets for Test acetaminophen taken orally one time
Intervention MeSH terms: Acetaminophen; Ibuprofen
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Molar,third; Teeth,wisdom; Pain, Postoperative; Dental Surgery; Third molar extraction
Ph IIA Study (SOC +/- NS5B)
Condition: Hepatitis C Virus
MeSH terms: Hepatitis C; Hepatitis
Study type: Interventional
Phase: Phase 2

Summary: 
      At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and
      efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the
      treatment of treatment-naïve, chronically-infected hepatitis C virus (HCV) genotype 1
      subjects
    


Intervention name(s): BMS-791325; BMS-791325; Placebo; Peg-interferon alfa-2a; Ribavirin
Intervention type(s): Drug; Drug; Drug; Drug; Drug
Intervention description(s): Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response; Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response; Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response; Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response; Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
Other intervention name(s): Pegasys; Copegus
Intervention MeSH terms: Interferons; Ribavirin; Interferon-alpha; Interferon alpha-2; Peginterferon alfa-2a
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Effects of Glucosamine and Chondroitin Sulfate Supplementation in Addition to Resistance Exercise Training and Manual Therapy in Patients With Knee Osteoarthritis
Condition: Osteoarthritis; Osteoarthritis, Knee
MeSH terms: Osteoarthritis; Osteoarthritis, Knee
Study type: Interventional

Summary: 
      Osteoarthritis (OA) IS one of the most common joint disorders, affecting not only the joints
      but also the surrounding muscles, which become weak. Resistance exercise reduces pain and
      improves function in patients with OA of the knee. Nonsteroidal anti-inflammatory drugs
      (NSAIDs) are widely used by patients with OA to reduce pain and thereby maintain the ability
      to perform daily activities. However, there is accumulating evidence for a negative effect of
      NSAIDs, thus many patients with OA are treated with dietary supplementations such as
      glucosamine and chondroitin sulfate, and some studies show a beneficial effects on cartilage
      and pain. However, their effect on OA symptoms and cartilage remains controversial. Thus, it
      is important to investigate whether a potentially beneficial effect of glucosamine and
      chondroitin sulfate with resistance exercise and manual therapy in patients with knee OA.
    


Intervention name(s): Chondroitin Sulfate; Resistance exercise training; Manual therapy / Joint Mobilization; THE therapy
Intervention type(s): Dietary Supplement; Procedure; Procedure; Procedure
Intervention description(s): Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day; Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)
Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval; Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization; Interferential and Heating for 20 min
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: chondroitin sulfate; resistance exercise; strength training; manual therapy; glucosamine; joint mobilization
Effects of Glucagon-Like Peptide-1 Analogs on Sexuality
Condition: Sexual Functioning
Study type: Interventional
Phase: Phase 2

Summary: 
      This placebo-controlled, double-blind crossover study is to evaluate the GLP-1 analogue
      dulaglutide regarding changes in sexuality, the mood and the reproductive axis in healthy
      men.
    

Detailed description: 
      This placebo-controlled, double-blind crossover study is to evaluate the GLP-1 analogue
      dulaglutide regarding changes in sexuality, the mood and the reproductive axis in healthy
      men.

      The study consists of following two phases:

        -  Phase a (V1a-Ev2a): baseline evaluation (V1a), application of the trial medication
           (dulaglutide or placebo) during 4 weeks (V1a-V4a), evaluation of the primary and
           secondary outcomes (V2a-V4a, Ev1a), followed by a washout period of at minimum 28 days
           before evaluation of the last secondary outcome (Ev2a) and cross-over

        -  Phase b (V1b-Ev2b): baseline evaluation (V1b), application of the trial medication
           (dulaglutide or placebo) during further 4 weeks (V1b-V4b), evaluation of the primary and
           secondary outcomes (V2b-V4b, Ev1b), followed by a washout period of at minimum 28 days
           before evaluation of the last secondary outcome (Ev2b) and study end after study
           termination visit (STV).
    

Intervention name(s): Dulaglutide; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.; Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
Intervention MeSH terms: Dulaglutide
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: randomized, double-blind, placebo-controlled trial with crossover design: Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Basic Science
Keywords: dulaglutide; Glucagon-like peptide-1 (GLP-1) analogs; Massachusetts General Hospital - Sexual Functioning Questionnaire (MGH-SFQ); GLP-1 receptor
Trial of Auto Continuous Positive Airway Pressure (CPAP)
Condition: Obstructive Sleep Apnea
MeSH terms: Sleep Apnea Syndromes; Sleep Apnea, Obstructive
Study type: Interventional
Phase: Phase 1

Summary: 
      Background: In patients with obstructive sleep apnea, automatic continuous positive airway
      pressure machines (autoCPAP) are said to be capable of identifying various breathing
      abnormalities during sleep and to correct them by increasing progressively the positive
      pressure applied to the airway. Once breathing becomes normal, pressure slowly declines.
      AutoCPAP devices have never been tested in Phase I studies. The investigators hypothesised
      that normal breathing would not be recognised as such, and that pressure would increase even
      in a normal subject.
    

Detailed description: 
      Material and Methods: We will submit one normal (confirmed with two polysomnographies, PSG)
      subject to a double blind study. Pairs of PSG will be performed on successive days once a
      week, one night with a 4 cm water fixed pressure CPAP device, previously shown not to disturb
      the subject's sleep and breathing, the other night with one of five well known autoCPAP
      devices programmed to work between 4 and 15 cm H2O pressure. The same mask and headgear will
      be used throughout the study. The subject and the physicians reading the tracings will ignore
      which device is being used on which night.
    

Intervention name(s): CPAP; autoCPAP
Intervention type(s): Device; Device
Intervention description(s): CPAP at 4 cm H2O; autoCPAP working between 4 and 15 cm H2O
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: treatment; CPAP; sleep apnea
Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)
Condition: Post Operative Pain
MeSH terms: Pain, Postoperative
Study type: Interventional
Phase: Phase 4

Summary: 
      Both morphine and hydromorphone are pain medications commonly used after surgery. It is
      thought at the institution that hydromorphone causes less side effects but this has not been
      studied. The study proposes to treat the patients with either morphine or hydromorphone and
      determine how much nausea, vomiting, and itching they have with each drug
    


Intervention name(s): Morphine PCA; Hydromorphone PCA
Intervention type(s): Drug; Drug
Intervention description(s): Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL; hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
Other intervention name(s): Astramorph PF; Duramorph; Infumorph; Dilaudid
Intervention MeSH terms: Morphine; Hydromorphone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: pain; morphine; hydromorphone; nausea; vomiting; pruritis
Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD
Condition: Coronary Artery Disease (CAD)
MeSH terms: Coronary Artery Disease; Myocardial Ischemia; Coronary Disease
Study type: Interventional
Phase: Phase 2

Summary: 
      The diagnostic efficacy and safety of the XTR004 myocardial perfusion PET imaging tracer are
      evaluated for known or suspected CAD with the use of invasive coronary angiography as the
      reference standard for the diagnosis of CAD and invasive pressure-temperature FFR/IMR as a
      reference for the detection of abnormal coronary function.
    

Detailed description: 
      A phase II study that is single-arm, open-label, multi-center, and self-controlled with the
      following objectives;

        1. Quantitative diagnostic efficacy of XTR004 perfusion imaging tracer in the diagnosis of
           known or suspected CAD using invasive coronary angiography as a reference standard for
           CAD.

        2. The effectiveness of XTR004 myocardial perfusion imaging tracer in the detection of CAD
           using a pressure-temperature guide wire fractional flow reserve (FFR), and index of
           microcirculation resistance (IMR) as a reference standard to confirm abnormal coronary
           blood flow reserve and microvascular disfunction.

        3. Subjects' safety after two doses of XTR004 intravenous injection.
    

Intervention name(s): XTR004
Intervention type(s): Drug
Intervention description(s): At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi
At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: coronary artery disease(CAD); positron emission tomography (PET)